Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.

F. László, L. Baláspiri

Research output: Contribution to journalArticle

Abstract

A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalActa Medica Hungarica
Volume43
Issue number3
Publication statusPublished - 1986

Fingerprint

Water Intoxication
Inappropriate ADH Syndrome
Deamino Arginine Vasopressin
Hyponatremia
Arginine Vasopressin
Brain Edema
Valine
Drinking
Water
Pharmaceutical Preparations
Antidiuretic Hormone Receptor Antagonists
1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(O-ethyl-Tyr)-4-Val-arginine vasopressin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP. / László, F.; Baláspiri, L.

In: Acta Medica Hungarica, Vol. 43, No. 3, 1986, p. 333-339.

Research output: Contribution to journalArticle

@article{89f7708df3394de486bbf29bfdc7e132,
title = "Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.",
abstract = "A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.",
author = "F. L{\'a}szl{\'o} and L. Bal{\'a}spiri",
year = "1986",
language = "English",
volume = "43",
pages = "333--339",
journal = "Acta Medica Hungarica",
issn = "0236-5286",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.

AU - László, F.

AU - Baláspiri, L.

PY - 1986

Y1 - 1986

N2 - A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.

AB - A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0022832178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022832178&partnerID=8YFLogxK

M3 - Article

C2 - 3588172

AN - SCOPUS:0022832178

VL - 43

SP - 333

EP - 339

JO - Acta Medica Hungarica

JF - Acta Medica Hungarica

SN - 0236-5286

IS - 3

ER -